234 related articles for article (PubMed ID: 24499724)
1. Overexpression of MYC and EZH2 cooperates to epigenetically silence MST1 expression.
Kuser-Abali G; Alptekin A; Cinar B
Epigenetics; 2014 Apr; 9(4):634-43. PubMed ID: 24499724
[TBL] [Abstract][Full Text] [Related]
2. EZH2 dependent H3K27me3 is involved in epigenetic silencing of ID4 in prostate cancer.
Chinaranagari S; Sharma P; Chaudhary J
Oncotarget; 2014 Aug; 5(16):7172-82. PubMed ID: 25115397
[TBL] [Abstract][Full Text] [Related]
3. Yin Yang 1-mediated epigenetic silencing of tumour-suppressive microRNAs activates nuclear factor-κB in hepatocellular carcinoma.
Tsang DP; Wu WK; Kang W; Lee YY; Wu F; Yu Z; Xiong L; Chan AW; Tong JH; Yang W; Li MS; Lau SS; Li X; Lee SD; Yang Y; Lai PB; Yu DY; Xu G; Lo KW; Chan MT; Wang H; Lee TL; Yu J; Wong N; Yip KY; To KF; Cheng AS
J Pathol; 2016 Apr; 238(5):651-64. PubMed ID: 26800240
[TBL] [Abstract][Full Text] [Related]
4. The EZH2- H3K27me3-DNMT1 complex orchestrates epigenetic silencing of the wwc1 gene, a Hippo/YAP pathway upstream effector, in breast cancer epithelial cells.
Liu X; Li C; Zhang R; Xiao W; Niu X; Ye X; Li Z; Guo Y; Tan J; Li Y
Cell Signal; 2018 Nov; 51():243-256. PubMed ID: 30121333
[TBL] [Abstract][Full Text] [Related]
5. Polycomb protein EZH2 suppresses apoptosis by silencing the proapoptotic miR-31.
Zhang Q; Padi SK; Tindall DJ; Guo B
Cell Death Dis; 2014 Oct; 5(10):e1486. PubMed ID: 25341040
[TBL] [Abstract][Full Text] [Related]
6. Coordinated silencing of MYC-mediated miR-29 by HDAC3 and EZH2 as a therapeutic target of histone modification in aggressive B-Cell lymphomas.
Zhang X; Zhao X; Fiskus W; Lin J; Lwin T; Rao R; Zhang Y; Chan JC; Fu K; Marquez VE; Chen-Kiang S; Moscinski LC; Seto E; Dalton WS; Wright KL; Sotomayor E; Bhalla K; Tao J
Cancer Cell; 2012 Oct; 22(4):506-523. PubMed ID: 23079660
[TBL] [Abstract][Full Text] [Related]
7. A central role for G9a and EZH2 in the epigenetic silencing of cyclooxygenase-2 in idiopathic pulmonary fibrosis.
Coward WR; Feghali-Bostwick CA; Jenkins G; Knox AJ; Pang L
FASEB J; 2014 Jul; 28(7):3183-96. PubMed ID: 24652950
[TBL] [Abstract][Full Text] [Related]
8. Myc enforces overexpression of EZH2 in early prostatic neoplasia via transcriptional and post-transcriptional mechanisms.
Koh CM; Iwata T; Zheng Q; Bethel C; Yegnasubramanian S; De Marzo AM
Oncotarget; 2011 Sep; 2(9):669-83. PubMed ID: 21941025
[TBL] [Abstract][Full Text] [Related]
9. Scaffold attachment factor B1 regulates the androgen receptor in concert with the growth inhibitory kinase MST1 and the methyltransferase EZH2.
Mukhopadhyay NK; Kim J; You S; Morello M; Hager MH; Huang WC; Ramachandran A; Yang J; Cinar B; Rubin MA; Adam RM; Oesterreich S; Di Vizio D; Freeman MR
Oncogene; 2014 Jun; 33(25):3235-45. PubMed ID: 23893242
[TBL] [Abstract][Full Text] [Related]
10. Histone trimethylation of the p53 gene by expression of a constitutively active prolactin receptor in prostate cancer cells.
Tan D; Tan S; Zhang J; Tang P; Huang J; Zhou W; Wu S
Chin J Physiol; 2013 Oct; 56(5):282-90. PubMed ID: 24032713
[TBL] [Abstract][Full Text] [Related]
11. EZH2-mediated inactivation of IFN-γ-JAK-STAT1 signaling is an effective therapeutic target in MYC-driven prostate cancer.
Wee ZN; Li Z; Lee PL; Lee ST; Lim YP; Yu Q
Cell Rep; 2014 Jul; 8(1):204-16. PubMed ID: 24953652
[TBL] [Abstract][Full Text] [Related]
12. The SRA protein UHRF1 promotes epigenetic crosstalks and is involved in prostate cancer progression.
Babbio F; Pistore C; Curti L; Castiglioni I; Kunderfranco P; Brino L; Oudet P; Seiler R; Thalman GN; Roggero E; Sarti M; Pinton S; Mello-Grand M; Chiorino G; Catapano CV; Carbone GM; Bonapace IM
Oncogene; 2012 Nov; 31(46):4878-87. PubMed ID: 22330138
[TBL] [Abstract][Full Text] [Related]
13. Polycomb- and Methylation-Independent Roles of EZH2 as a Transcription Activator.
Kim J; Lee Y; Lu X; Song B; Fong KW; Cao Q; Licht JD; Zhao JC; Yu J
Cell Rep; 2018 Dec; 25(10):2808-2820.e4. PubMed ID: 30517868
[TBL] [Abstract][Full Text] [Related]
14. A key role for EZH2 in epigenetic silencing of HOX genes in mantle cell lymphoma.
Kanduri M; Sander B; Ntoufa S; Papakonstantinou N; Sutton LA; Stamatopoulos K; Kanduri C; Rosenquist R
Epigenetics; 2013 Dec; 8(12):1280-8. PubMed ID: 24107828
[TBL] [Abstract][Full Text] [Related]
15. Silencing or inhibition of H3K79 methyltransferase DOT1L induces cell cycle arrest by epigenetically modulating c-Myc expression in colorectal cancer.
Yang L; Lei Q; Li L; Yang J; Dong Z; Cui H
Clin Epigenetics; 2019 Dec; 11(1):199. PubMed ID: 31888761
[TBL] [Abstract][Full Text] [Related]
16. EZH2-induced H3K27me3 is associated with epigenetic repression of the ARHI tumor-suppressor gene in ovarian cancer.
Fu Y; Chen J; Pang B; Li C; Zhao J; Shen K
Cell Biochem Biophys; 2015 Jan; 71(1):105-12. PubMed ID: 25077680
[TBL] [Abstract][Full Text] [Related]
17. BRCA1 and EZH2 cooperate in regulation of prostate cancer stem cell phenotype.
Gorodetska I; Lukiyanchuk V; Peitzsch C; Kozeretska I; Dubrovska A
Int J Cancer; 2019 Dec; 145(11):2974-2985. PubMed ID: 30968962
[TBL] [Abstract][Full Text] [Related]
18. Global levels of H3K27me3 track with differentiation in vivo and are deregulated by MYC in prostate cancer.
Pellakuru LG; Iwata T; Gurel B; Schultz D; Hicks J; Bethel C; Yegnasubramanian S; De Marzo AM
Am J Pathol; 2012 Aug; 181(2):560-9. PubMed ID: 22713676
[TBL] [Abstract][Full Text] [Related]
19. Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer.
Varambally S; Cao Q; Mani RS; Shankar S; Wang X; Ateeq B; Laxman B; Cao X; Jing X; Ramnarayanan K; Brenner JC; Yu J; Kim JH; Han B; Tan P; Kumar-Sinha C; Lonigro RJ; Palanisamy N; Maher CA; Chinnaiyan AM
Science; 2008 Dec; 322(5908):1695-9. PubMed ID: 19008416
[TBL] [Abstract][Full Text] [Related]
20. Mutations and deletions of PRC2 in prostate cancer.
Jain P; Di Croce L
Bioessays; 2016 May; 38(5):446-54. PubMed ID: 27000413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
